Загрузка...
Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917
CS-917 (MB06322) is a selective small compound inhibitor of fructose 1,6-bisphosphatase (FBPase), which is expected to be a novel drug for the treatment of type 2 diabetes by inhibiting gluconeogenesis. CS-917 is a bisamidate prodrug and activation of CS-917 requires a two-step enzyme catalyzed reac...
Сохранить в:
| Опубликовано в: : | Pharmacol Res Perspect |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Ltd
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4492754/ https://ncbi.nlm.nih.gov/pubmed/26171222 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.138 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|